MX2021007835A - Polipeptidos utiles para edicion de genes y metodos de uso. - Google Patents

Polipeptidos utiles para edicion de genes y metodos de uso.

Info

Publication number
MX2021007835A
MX2021007835A MX2021007835A MX2021007835A MX2021007835A MX 2021007835 A MX2021007835 A MX 2021007835A MX 2021007835 A MX2021007835 A MX 2021007835A MX 2021007835 A MX2021007835 A MX 2021007835A MX 2021007835 A MX2021007835 A MX 2021007835A
Authority
MX
Mexico
Prior art keywords
interest
target sequence
binding
compositions
crispr
Prior art date
Application number
MX2021007835A
Other languages
English (en)
Inventor
Michael Lassner
Mark Moore
Tyson D Bowen
Tedd D Elich
Alexandra Briner Crawley
Rodolphe Barrangou
Original Assignee
Lifeedit Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifeedit Therapeutics Inc filed Critical Lifeedit Therapeutics Inc
Publication of MX2021007835A publication Critical patent/MX2021007835A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04004—Adenosine deaminase (3.5.4.4)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se proporcionan composiciones y métodos de unión con una secuencia diana de interés. Las composiciones incluyen proteínas de fusión entre proteínas de unión a ADN o dominios de proteína y proteínas que modifican ácidos nucleicos o dominios de proteínas. Las composiciones se usan en la escisión o la modificación de una secuencia diana de interés, visualización de una secuencia diana de interés y la modificación de la expresión de una secuencia de interés. Las composiciones comprenden polipéptidos de nucleasa guiados por ARN, ARN de CRISPR, ARN de CRISPR transactivantes, ARN de guía, desaminasas y moléculas de ácido nucleico que los codifican. También se proporcionan vectores y células hospederas que comprenden las moléculas de ácido nucleico. También se proporcionan sistemas de CRISPR para unir una secuencia diana de interés, en donde el sistema de CRISPR comprende un polipéptido de nucleasa guiado por ARN y uno o más ARN de guía. También se proporcionan desaminasas que se pueden fusionar con un polipéptido de unión a ADN y también pueden ser de utilidad para la edición de genes.
MX2021007835A 2018-12-27 2019-12-20 Polipeptidos utiles para edicion de genes y metodos de uso. MX2021007835A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201862785391P 2018-12-27 2018-12-27
US201962790266P 2019-01-09 2019-01-09
US201962790256P 2019-01-09 2019-01-09
US201962790262P 2019-01-09 2019-01-09
US201962790258P 2019-01-09 2019-01-09
US201962790261P 2019-01-09 2019-01-09
US201962932169P 2019-11-07 2019-11-07
PCT/US2019/068079 WO2020139783A2 (en) 2018-12-27 2019-12-20 Polypeptides useful for gene editing and methods of use

Publications (1)

Publication Number Publication Date
MX2021007835A true MX2021007835A (es) 2021-08-11

Family

ID=69182752

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007835A MX2021007835A (es) 2018-12-27 2019-12-20 Polipeptidos utiles para edicion de genes y metodos de uso.

Country Status (14)

Country Link
US (2) US20220145296A1 (es)
EP (2) EP4339286A2 (es)
JP (2) JP2022516130A (es)
KR (1) KR20210149686A (es)
CN (1) CN113631704A (es)
AU (1) AU2019416108A1 (es)
BR (1) BR112021012665A2 (es)
ES (1) ES2970169T3 (es)
IL (1) IL284400A (es)
MX (1) MX2021007835A (es)
SG (1) SG11202106977PA (es)
TW (1) TW202039847A (es)
WO (1) WO2020139783A2 (es)
ZA (1) ZA202105281B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202208626A (zh) 2020-04-24 2022-03-01 美商生命編輯公司 Rna引導核酸酶及其活性片段與變體，以及使用方法
TW202216998A (zh) 2020-07-01 2022-05-01 美商艾勒維生技公司 使用環狀rna之細胞重編程之組合物及方法
IL299812A (en) 2020-07-15 2023-03-01 Lifeedit Therapeutics Inc Uracil stabilizing proteins and active fragments and their variants and methods of use
AU2021339805A1 (en) 2020-09-11 2023-05-25 LifeEDIT Therapeutics, Inc. Dna modifying enzymes and active fragments and variants thereof and methods of use
CN117295817A (zh) 2021-03-22 2023-12-26 生命编辑制药股份有限公司 Dna修饰酶及其活性片段和变体以及使用方法
KR20240021218A (ko) * 2021-06-11 2024-02-16 바이엘 악티엔게젤샤프트 신규 유형 v rna 프로그래밍가능 엔도뉴클레아제 시스템
CA3173953A1 (en) 2021-06-11 2023-12-10 Tyson D. BOWEN Rna polymerase iii promoters and methods of use
EP4101928A1 (en) * 2021-06-11 2022-12-14 Bayer AG Type v rna programmable endonuclease systems
WO2023031856A1 (en) 2021-09-02 2023-03-09 Sanofi Compositions and methods for rna affinity purification
KR20240065326A (ko) 2021-10-05 2024-05-14 사노피 지질 나노입자(ｌｎｐ)를 냉동 및 냉동-건조하는 방법 및 이를 사용하여 수득된 ｌｎｐ
WO2023118068A1 (en) * 2021-12-23 2023-06-29 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2023135305A1 (en) 2022-01-17 2023-07-20 Sanofi Lipidic compounds, and uses thereof
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023242425A1 (en) 2022-06-17 2023-12-21 Sanofi Compositions and methods for circular rna affinity purification
WO2024020346A2 (en) 2022-07-18 2024-01-25 Renagade Therapeutics Management Inc. Gene editing components, systems, and methods of use
WO2024033901A1 (en) 2022-08-12 2024-02-15 LifeEDIT Therapeutics, Inc. Rna-guided nucleases and active fragments and variants thereof and methods of use
WO2024042489A1 (en) 2022-08-25 2024-02-29 LifeEDIT Therapeutics, Inc. Chemical modification of guide rnas with locked nucleic acid for rna guided nuclease-mediated gene editing
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024095245A2 (en) 2022-11-04 2024-05-10 LifeEDIT Therapeutics, Inc. Evolved adenine deaminases and rna-guided nuclease fusion proteins with internal insertion sites and methods of use
WO2024127369A1 (en) 2022-12-16 2024-06-20 LifeEDIT Therapeutics, Inc. Guide rnas that target foxp3 gene and methods of use
WO2024127370A1 (en) 2022-12-16 2024-06-20 LifeEDIT Therapeutics, Inc. Guide rnas that target trac gene and methods of use

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5380831A (en) 1986-04-04 1995-01-10 Mycogen Plant Science, Inc. Synthetic insecticidal crystal protein gene
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5569597A (en) 1985-05-13 1996-10-29 Ciba Geigy Corp. Methods of inserting viral DNA into plant material
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4853331A (en) 1985-08-16 1989-08-01 Mycogen Corporation Cloning and expression of Bacillus thuringiensis toxin gene toxic to beetles of the order Coleoptera
US5268463A (en) 1986-11-11 1993-12-07 Jefferson Richard A Plant promoter α-glucuronidase gene construct
US5608142A (en) 1986-12-03 1997-03-04 Agracetus, Inc. Insecticidal cotton plants
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5039523A (en) 1988-10-27 1991-08-13 Mycogen Corporation Novel Bacillus thuringiensis isolate denoted B.t. PS81F, active against lepidopteran pests, and a gene encoding a lepidopteran-active toxin
EP0463056A1 (en) 1989-03-17 1992-01-02 E.I. Du Pont De Nemours And Company External regulation of gene expression
DE69133128T2 (de) 1990-04-12 2003-06-18 Syngenta Participations Ag Gewebe-spezifische Promotoren
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5498830A (en) 1990-06-18 1996-03-12 Monsanto Company Decreased oil content in plant seeds
CA2051562C (en) 1990-10-12 2003-12-02 Jewel M. Payne Bacillus thuringiensis isolates active against dipteran pests
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5399680A (en) 1991-05-22 1995-03-21 The Salk Institute For Biological Studies Rice chitinase promoter
DE69230290T2 (de) 1991-08-27 2000-07-20 Novartis Ag Proteine mit insektiziden eigenschaften gegen homopteran insekten und ihre verwendung im pflanzenschutz
TW261517B (es) 1991-11-29 1995-11-01 Mitsubishi Shozi Kk
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5789156A (en) 1993-06-14 1998-08-04 Basf Ag Tetracycline-regulated transcriptional inhibitors
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5608144A (en) 1994-08-12 1997-03-04 Dna Plant Technology Corp. Plant group 2 promoters and uses thereof
US5659026A (en) 1995-03-24 1997-08-19 Pioneer Hi-Bred International ALS3 promoter
US6072050A (en) 1996-06-11 2000-06-06 Pioneer Hi-Bred International, Inc. Synthetic promoters
AR014072A1 (es) 1998-02-26 2001-01-31 Pioneer Hi Bred Int Molecula de acido nucleico aislada que tiene una secuencia nucleotidica para un promotor que es capaz de iniciar una transcripcion constitutiva en unacelula de planta, construccion adn, vector, celula huesped, metodo para expresar en forma constitutiva una secuencia nucleotidica heteroloca en una
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
EP1173578A2 (en) 1999-05-04 2002-01-23 Monsanto Company Coleopteran-toxic polypeptide compositions and insect-resistant transgenic plants
EP1218513A2 (en) 1999-09-15 2002-07-03 Monsanto Technology LLC Lepidopteran-active bacillus thuringiensis delta-endotoxin compositions and methods of use
AU2002360291A1 (en) 2001-12-17 2003-06-30 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 8 sequences
US20050183161A1 (en) 2003-10-14 2005-08-18 Athenix Corporation AXMI-010, a delta-endotoxin gene and methods for its use
US7629504B2 (en) 2003-12-22 2009-12-08 Pioneer Hi-Bred International, Inc. Bacillus thuringiensis cry9 nucleic acids
WO2007147029A2 (en) 2006-06-14 2007-12-21 Athenix Corporation Axmi-031, axmi-039, axmi-040 and axmi-049, a family of delta-endotoxin genes and methods for their use
ES2615829T3 (es) 2008-09-15 2017-06-08 The Children's Medical Center Corporation Modulación de BCL11A para el tratamiento de hemoglobinopatías
WO2010132092A2 (en) 2009-05-12 2010-11-18 The Scripps Research Institute Cytidine deaminase fusions and related methods
US8575425B2 (en) 2009-07-02 2013-11-05 Athenix Corporation AXMI-205 pesticidal gene and methods for its use
US8586832B2 (en) 2009-12-21 2013-11-19 Pioneer Hi Bred International Inc Bacillus thuringiensis gene with Lepidopteran activity
MX2013001742A (es) 2010-08-19 2013-05-14 Pioneer Hi Bred Int Nuevo gen de bacillus thuringiensis con actividad lepidoptera
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
UA118014C2 (uk) * 2012-05-25 2018-11-12 Те Ріджентс Оф Те Юніверсіті Оф Каліфорнія Спосіб модифікації днк-мішені
EP2872625B1 (en) 2012-07-11 2016-11-16 Sangamo BioSciences, Inc. Methods and compositions for the treatment of lysosomal storage diseases
SG10201912327SA (en) * 2012-12-12 2020-02-27 Broad Inst Inc Engineering and Optimization of Improved Systems, Methods and Enzyme Compositions for Sequence Manipulation
US20150166985A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting von willebrand factor point mutations
WO2016033298A1 (en) 2014-08-28 2016-03-03 North Carolina State University Novel cas9 proteins and guiding features for dna targeting and genome editing
AU2015101792A4 (en) * 2014-12-24 2016-01-28 Massachusetts Institute Of Technology Engineering of systems, methods and optimized enzyme and guide scaffolds for sequence manipulation
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
WO2017062855A1 (en) * 2015-10-09 2017-04-13 Monsanto Technology Llc Novel rna-guided nucleases and uses thereof
US20190225955A1 (en) 2015-10-23 2019-07-25 President And Fellows Of Harvard College Evolved cas9 proteins for gene editing
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
CN109957569B (zh) * 2017-12-22 2022-10-25 苏州齐禾生科生物科技有限公司 基于cpf1蛋白的碱基编辑系统和方法

Also Published As

Publication number Publication date
KR20210149686A (ko) 2021-12-09
EP3902911C0 (en) 2023-12-13
EP3902911B1 (en) 2023-12-13
SG11202106977PA (en) 2021-07-29
JP2022516130A (ja) 2022-02-24
BR112021012665A2 (pt) 2021-11-03
ZA202105281B (en) 2024-05-30
US20220145296A1 (en) 2022-05-12
ES2970169T3 (es) 2024-05-27
IL284400A (en) 2021-08-31
WO2020139783A3 (en) 2020-07-23
US20230272398A1 (en) 2023-08-31
TW202039847A (zh) 2020-11-01
AU2019416108A1 (en) 2021-08-12
CN113631704A (zh) 2021-11-09
JP2024050676A (ja) 2024-04-10
WO2020139783A2 (en) 2020-07-02
EP4339286A2 (en) 2024-03-20
EP3902911A2 (en) 2021-11-03

Similar Documents

Publication Publication Date Title
ZA202105281B (en) Polypeptides useful for gene editing and methods of use
MX2020013124A (es) Nucleasas guiadas por acido ribonucleico (arn) y fragmentos activos y variantes de los mismos y metodos de uso.
MX2022001849A (es) Nucleasas guiadas por acido ribonucleico (arn) y sus fragmentos activos y variantes y metodos de uso.
WO2022056254A3 (en) Dna modifying enzymes and active fragments and variants thereof and methods of use
EP4321617A3 (en) Crispr/cpf1 systems and methods
Dalvai et al. A scalable genome-editing-based approach for mapping multiprotein complexes in human cells
WO2017070633A3 (en) Evolved cas9 proteins for gene editing
PH12019501335A1 (en) Thermostable cas9 nucleases
MX2019004499A (es) Sistemas de replicón de virus recombinante y usos de estos.
MX2022013187A (es) Nucleasas guiadas por acido ribonucleico (arn) y sus fragmentos activos y variantes y metodos de uso.
PH12021551114A1 (en) Crispr-cas12j enzyme and system
MX2023003125A (es) Proteinas multiespecificas de union al antigeno.
PH12019500122A1 (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
HRP20240408T1 (hr) Inzulin-fc fuzijski proteini ultradugog djelovanja i metode uporabe
WO2019084362A3 (en) Fusion protein and nucleic acid molecule for exogenous stimulant-dependent stress granule assembly
MX356162B (es) Sistema de expresion y secrecion.
PH12017502080A1 (en) Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same
MX2023002160A (es) Proteinas dise?adas y metodos de uso de las mismas.
MX2022002956A (es) Sistemas y métodos para expresión de proteínas.
AR125191A1 (es) Enzimas modificadoras del adn y sus fragmentos activos y variantes y métodos de uso
WO2020006131A3 (en) Nucleases for genome editing
EA202191788A1 (ru) Полипептиды, применимые для редактирования генов, и способы их применения
ATE288488T1 (de) Zusammensetzungen und verfahren zur eliminierung unerwünschter zellen
AR117535A1 (es) Polipéptidos útiles para edición de genes y métodos de uso
EA202092929A1 (ru) Рнк-управляемые нуклеазы и активные фрагменты и их варианты и способы применения